ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
Immune checkpoint inhibitors (ICIs) are increasingly being used to manage multiple tumor types. Unfortunately, immune-related adverse events affect up to 60% of recipients, often leading to treatment discontinuation in settings where few alternative cancer therapies may be available. Checkpoint inhibitor induced colitis (ICI-colitis) is a common toxicity for which the underlying mechanisms are poorly defined. To better understand the changing colon-specific and peripheral immune environments over the course of progression and treatment of colitis, we collected blood and colon tissue from a patient with Merkel cell carcinoma who developed colitis on treatment with pembrolizumab. We performed single-cell RNA sequencing and T-cell receptor sequencing on samples collected before, during and after pembrolizumab and after various interventions to mitigate toxicity. We report T-cells populations defined by cytotoxicity, memory, and proliferation markers at various stages of colitis. We show preferential depletion of CD8+ T cells with biologic therapy and nominate both circulating and colon-resident T-cell subsets as potential drivers of inflammation and response to immune suppression. Our findings highlight the need for further exploration of the colon immune environment and rationalize future studies evaluating biologics for ICI-colitis, including in the context of ICI re-challenge.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal for immunotherapy of cancer - 11(2023), 8 vom: 08. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mann, Jacqueline E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CD8-Positive T-Lymphocytes |
|---|
| Anmerkungen: |
Date Completed 18.08.2023 Date Revised 27.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1136/jitc-2023-007358 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360859631 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360859631 | ||
| 003 | DE-627 | ||
| 005 | 20240427231951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jitc-2023-007358 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1390.xml |
| 035 | |a (DE-627)NLM360859631 | ||
| 035 | |a (NLM)37586769 | ||
| 035 | |a (PII)e007358 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mann, Jacqueline E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.08.2023 | ||
| 500 | |a Date Revised 27.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Immune checkpoint inhibitors (ICIs) are increasingly being used to manage multiple tumor types. Unfortunately, immune-related adverse events affect up to 60% of recipients, often leading to treatment discontinuation in settings where few alternative cancer therapies may be available. Checkpoint inhibitor induced colitis (ICI-colitis) is a common toxicity for which the underlying mechanisms are poorly defined. To better understand the changing colon-specific and peripheral immune environments over the course of progression and treatment of colitis, we collected blood and colon tissue from a patient with Merkel cell carcinoma who developed colitis on treatment with pembrolizumab. We performed single-cell RNA sequencing and T-cell receptor sequencing on samples collected before, during and after pembrolizumab and after various interventions to mitigate toxicity. We report T-cells populations defined by cytotoxicity, memory, and proliferation markers at various stages of colitis. We show preferential depletion of CD8+ T cells with biologic therapy and nominate both circulating and colon-resident T-cell subsets as potential drivers of inflammation and response to immune suppression. Our findings highlight the need for further exploration of the colon immune environment and rationalize future studies evaluating biologics for ICI-colitis, including in the context of ICI re-challenge | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a CD8-Positive T-Lymphocytes | |
| 650 | 4 | |a Immune Checkpoint Inhibitors | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Programmed Cell Death 1 Receptor | |
| 650 | 4 | |a T-Lymphocytes | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Lucca, Liliana |e verfasserin |4 aut | |
| 700 | 1 | |a Austin, Matthew R |e verfasserin |4 aut | |
| 700 | 1 | |a Merkin, Ross D |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, Marie E |e verfasserin |4 aut | |
| 700 | 1 | |a Al Bawardy, Badr |e verfasserin |4 aut | |
| 700 | 1 | |a Raddassi, Khadir |e verfasserin |4 aut | |
| 700 | 1 | |a Aizenbud, Lilach |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Nikhil S |e verfasserin |4 aut | |
| 700 | 1 | |a Hafler, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Abraham, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Herold, Kevan C |e verfasserin |4 aut | |
| 700 | 1 | |a Kluger, Harriet M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal for immunotherapy of cancer |d 2013 |g 11(2023), 8 vom: 08. Aug. |w (DE-627)NLM23381065X |x 2051-1426 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:8 |g day:08 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/jitc-2023-007358 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 8 |b 08 |c 08 | ||